Trek Diagnostic Systems Ltd

Trek Diagnostic Systems Ltd specialises in in vitro diagnostic (IVD) products used for antimicrobial susceptibility testing. These include culture media, susceptibility testing plates, panels, and dosing heads designed to identify resistance patterns in microorganisms like *Haemophilus influenzae*, *Streptococcus pneumoniae*, and yeast species. The devices help clinical labs determine the most effective antimicrobial treatments by measuring how microbes respond to antibiotics.

Trek Diagnostic Systems Ltd is headquartered in the United Kingdom. Its devices are authorised for use in the European Union through the EUDAMED database and have undergone FDA 510(k) clearance, meaning they are also available in the United States. The company’s products comply with both EU MDR and FDA regulatory requirements, ensuring they meet the necessary standards for antimicrobial susceptibility testing in these markets.

Under the EU Medical Device Regulation (MDR), Trek Diagnostic Systems Ltd’s devices are classified as Class A, Class B, or Class II. Class A devices are generally low-risk, while Class B and Class II products carry higher risks due to their role in diagnosing antimicrobial resistance, which directly impacts patient treatment decisions. In the U.S., these devices have been cleared via the FDA’s 510(k) premarket notification process, demonstrating their safety and effectiveness for their intended use.

Trek Diagnostic Systems Ltd’s devices are listed in the EUDAMED database, which is the official European Union registry for medical devices. Additionally, the company’s products have undergone FDA 510(k) clearance, meaning they are also documented in the FDA’s premarket notification database. These listings confirm the devices’ regulatory status in both the EU and the U.S., ensuring transparency for healthcare providers and authorities.

The primary purpose of Trek Diagnostic Systems Ltd’s antimicrobial susceptibility testing products is to help clinical microbiology labs determine how effectively antibiotics can inhibit or kill specific microorganisms. By using their culture media, plates, and automated systems (like the SENSITITRE AIM), labs can identify resistance patterns, enabling healthcare providers to prescribe targeted treatments and reduce the risk of antibiotic-resistant infections. This supports better patient outcomes and more efficient use of antimicrobial therapies.